Company attributes
Other attributes
Eureka Therapeutics is a clinical-stage biopharmaceutical company that has the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system.
The company believes that T-cell therapy represents a revolutionary step towards providing a potential cure for several forms of cancer, including cancers that are poorly addressed by the current approaches. Eureka's mission is to develop safe and effective T-cell therapies that are broadly accessible to the patients as the standard of care for the treatment of several hematologic and solid tumors.
The company’s proprietary ARTEMIS® platform was created to mimic the natural biology of T-cells to fight cancer. Its ARTEMIS® platform is a novel T-cell therapy construct, that is intended to create safer and potentially more effective T-cell therapies than are currently available.
Eureka's proprietary E-ALPHA® antibody discovery platform comprises of a diverse human-derived antibody phage library of over 100 billion clones with unique antibody sequences and a robust workflow that is designed to enable the company to develop specific antibodies against target antigens, including peptide-MHC complexes and cell surface proteins.
Eureka Therapeutics is currently developing a pipeline of novel cancer therapeutics targeting intracellular and cell-surface targets.
